Cadex Genomics
Dr. Hall’s career started at Genentech where he was on the medical affairs team that launched Rituxan and Herceptin. Dr. Hall was also a member of the Rituxan and Herceptin clinical development teams at Genentech facilitating and monitoring clinical trials. At Genomic Health, Dr. Hall formed and led the medical science liaison team and was involved with the launch of the Breast, Colon and Prostate assays. Dr. Hall was the Executive Director of Medical Affairs at Castle Biosciences and the first Medical employee where he established a medical affairs team to support the company’s cutaneous melanoma test. He has more than 20 years of industry experience.
This person is not in any offices
Cadex Genomics
Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with cutting-edge technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws.